A study of weekly paclitaxel vs weekly cisplatin with concomitant chemoradiation in locally advanced head and neck cancer

Himadri Kumar Daru; Yumkhaibam Sobita Devi; Yumkhaibam Sobita Devi; Jaichand Singh; Jaichand Singh

doi:10.18203/2320-6012.ijrms20174941

Authors

Himadri Kumar Daru Department of Radiotherapy, Regional Cancer Centre, Agartala, Tripura, India
Yumkhaibam Sobita Devi Department of Radiotherapy, Regional institute of Medical Sciences, Imphal, Manipur, India
Yumkhaibam Sobita Devi Department of Radiotherapy, Regional institute of Medical Sciences, Imphal, Manipur, India
Jaichand Singh Department of Radiotherapy, Regional institute of Medical Sciences, Imphal, Manipur, India
Jaichand Singh Department of Radiotherapy, Regional institute of Medical Sciences, Imphal, Manipur, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20174941

Keywords:

Concomitant chemoradiotherapy, Paclitaxel, Locally advanced head and neck cancer

Abstract

Background: The purpose of this study was to compare the role of concomitant chemoradiation using paclitaxel versus cisplatin in locally advanced head and neck cancers.

Methods: 52 patients were randomly assigned to one of the two concomitant chemoradiation arms: arm I (n=26) and arm II (n= 26) who received injection of paclitaxel 40 mg/m2 I/V 1-hour infusion before radiation, repeated weekly for 6 cycles, and cisplatin 30 mg/m2 I/V 1-hour infusion before radiation, repeated weekly for 6 cycles, respectively. The planned radiotherapy dose was 66-70 Gy, 2 Gy/day, 5#/Week in 6-7 weeks.

Results: Response rates were 69.2% and 57.7% in arm I and arm II, respectively. There was no statistically significant difference observed between the study group and the control group (P = 0.85) On median follow up of 7-15 months, Disease free survival was (83.3%) in arm I compared with (73.3%) in arm II but the difference was statistically insignificant. Local toxicities including mucositis, dysphasia and skin reactions were more in the study the haematological toxicity was generally mild. On the contrary, non-hematologic toxicities were severe. Grade IV mucositis occurred in 26.9% in arm I and in 3.8% in arm II (P = 0.003). Moreover, grade IV dermatitis were encountered in 23.1% in arm I (P = 0.00).

Conclusions: Both concomitant chemoradiotherapy regimens were easily given in the outpatient clinic. The regimen based on paclitaxel was more effective; however, the difference was insignificant.

Metrics

Metrics Loading ...

References

International Agency for Research on Cancer GLOBOCAN, 2008. Available at: http://globocan .iarc.fr/Pages/fact_sheets_population.aspx. Accessed 27 January, 2014.

Trivedi NP, Kekatpure VD, Trivedi NN, Kuriakose MA. Head and neck cancer in India: Need to formulate uniform national treatment guideline. Indian J Cancer. 2012;49: 6-0.

Pignon JP,Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACHNC): an update on 93 randomised trials and 17,346 patients. Radio Ther Oncol. 2009;92:4-14.

Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18(7):1458-64.

Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer. Medic Oncol. 2004;21(2):95-107.

Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665-73.

Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head and neck Oncol. 2009;1(1):17.

Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). Int J Rad Oncol Bio Phys. 2011;81(3):719-25.

Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-8.

Al Saraf M. Head and neck cancer: chemotherapy concepts. Semi Oncol. 1988;15:70-85.

Laramore GE, Scott CB, al-Sarraf M. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on intergroup study 0034. Int J Rad Oncol Bio Phys. 1992;23:705-13.

Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nature Reviews. Clin Oncol. 2007;4(3):156.

Vokes EE, Weichselbaum RR, Lippman SM. Head and neck cancer. N Eng J Med. 1993; 328: 184-94.

Vokes EE, Weichselbaum RR. Measurable impact: multimodality therapy of head and neck cancer. Int J Rad Oncol Bio Phys. 1993;27:481-2.

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New Eng J Medic. 2004;350(19):1945-52.

Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Rad Oncol Bio Phys. 1996;36:999-04.

Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, Sarraf M,Mowry PA, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of head and neck. Cancer. 1990;66:1861-8.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Eng J Med. 2004;350:1937-44.

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Eng J Med. 2003;349:2091-8.

Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-8.

Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin P Oncol. 2007;4:86-100.

Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Rad Res. 1966;29:450-74.

Terasima T, Tolmach LJ. Changes in X-ray sensitivity of HeLa cells during the division cycle. Nature. 1961;190:1210-1.

Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998; 16: 1310-7.

Forastiere AA, Shank D, Neuberg D, Taylor SG, DeConti RC, Adams G, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer. 1998;82:2270-4.

Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semi Oncol. 1995;22(6):41-6.

Gebbia V, Testa A, Cannata G, Gebbia N. Single agent paclitaxel in advanced squamous cell head and neck carcinoma. Eur J Cancer. 1996;32:901-2.

Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2004;9:107-12.

Plasswilm L, Kirschner M, Sauer R. Concurrent Taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlenther Onkol. 1996;172(10):573-9.

Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, et al. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer. Results from a phase I trial. Int J Rad Oncol Bio Phys. 1997;38:691-6.

Steinberg L, Hassan M, Olmsted L. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semi Oncol. 1997;24(19):51-6.

Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglotic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCVA)protocol 5-85. Radio Oncol. 1988;46:135-46.

Wang Y, Wu KC, Zhao BX, Zhao X, Wang X, Chen S, et al. A novel paclitaxel microemulsion containing a reduced amount of cremophor el: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotech. 2011;1-10.

Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res.1996;56(22):5198-204.

Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Aca Sci USA. 1999;96:3775-80.

Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2011;41:980-6.

Bourhis J, Eschwege F. Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res. 1996;16:2397-2402.

Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squanous head and neck cancer. J Clin Oncol. 2001;19:1961-9.

Jain RK, Kirar P, Gupta G, Dubey S, Gupta SK, Goyal J. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers. Ind J Cancer. 2009;46(1):50-3.

Lovey J, Koronczay K, Remenar E, Csuka 0, Nemeth G. Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radio Oncol. 2003;68:171-4.

Tishler RB, Busse PM, Norris CM, Rossi R, Poulin M, Thornhill L, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Inter J Rad Oncol Bio Phy. 1999;43(5):1001-8.